en.Wedoany.com Reported - FedEx has established a new specialized division, FedEx Life Sciences, to serve healthcare and pharmaceutical transportation, a move the company hopes will attract investors more than improving performance.
FedEx reported its Q4 fiscal year 2026 results for the period ending May 31, showing quarterly revenue increased 12.5% year-over-year to $25.01 billion, exceeding the expected $24.04 billion; full-year revenue rose to $94.7 billion from $87.9 billion in the previous fiscal year. Daily package volume grew 2% in the quarter, while revenue per package jumped 11%, validating management's strategy of shifting from low-margin volume to higher-yield business—Ground Economy volume decreased by approximately 5% in the quarter.
Despite results surpassing Wall Street expectations, investors were not impressed. The stock fell 6% after the earnings call, with analysts noting that operating margin declined to 8.4% from 9.1% in the same period last year.
FedEx CEO Raj Subramaniam told analysts that the momentum demonstrated in the business proves the strategy is working, translating into favorable financial results, including strong free cash flow and full-year performance well above initial outlook. However, investors may have been more pleased with the news announced during the call: the newly formed FedEx Life Sciences division, aimed at enhancing support for complex, time-critical, and highly regulated healthcare supply chains. According to Chief Customer Officer Brie Carere, the division is part of FedEx's strategy to focus on high-yield business, built on a network of life sciences centers in Europe and Asia-Pacific. In fiscal year 2026, FedEx's revenue in this segment grew to nearly $10 billion from $9 billion in the previous fiscal year.
Competitor UPS is also expanding in the same field. In fiscal year 2025, UPS healthcare revenue was $11.2 billion, up from $10.5 billion a year earlier, and management has set a target of reaching $20 billion. UPS announced this week a $48 million investment in cold chain infrastructure to support healthcare transportation, with funds allocated to 27 temperature-controlled cross-dock facilities in the U.S., Europe, Asia, and the Americas. UPS stated these facilities meet CEIV Pharma standards and are supported by 24/7/365 control towers to monitor shipments and respond to disruptions. Kiel Harkness, Vice President of UPS Healthcare Strategy, noted that the growing portfolio of higher-value, temperature-controlled, and time-critical healthcare products requires more precise control within the supply chain.
Dedicated air services are also becoming a rising factor in this field. In September last year, FedEx announced plans to operate flights between Dublin and Indianapolis to transport medical products and other high-value goods, claiming it could reduce transit time by one day. In February this year, DHL launched a B777 freighter named "DHL Health Logistics," connecting Brussels and Cincinnati, with management deciding to shift a larger proportion of healthcare shipments to dedicated freighters, reducing reliance on commercial airlines. DHL said it plans to introduce more such services, targeting dedicated routes in Europe, the Middle East, Asia, and Latin America to form core elements of an air cargo cold chain network. Countries designated for expansion include India, Singapore, Japan, South Korea, Brazil, the United States, Germany, and Ireland.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
